Company: ARVN
Filing Date: 2025-02-11
Form Type: 10-K
Source: 0001655759-25-000016
Chunk: 51

Company: ARVINAS, INC.
Filing Date: 2025-02-11
Form: 10-K
Item: Item 16
Chunk 51
---
1.2 (0.2)Income tax expense0.6 0.9 20.9 Loss from equity method investment— 2.5 10.6 Plus:Interest income, net54.8 38.8 12.0 Segment net loss$(198.9)$(367.3)$(282.5)(*)    Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.(**)    Includes loss on disposal of fixed assets, realized gains/ losses on sale of marketable securities and refundable research and development credits from the State of Connecticut.  Depreciation expense totaled $4.6 million, $4.8 million, and $6.3 million for the years ended December 31, 2024, 2023 and 2022, respectively.

F - 29